Skip to main content

Table 3 Ongoing or recruiting studies in paediatric patients with inflammatory rheumatic diseases (July 2020)

From: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

Drug class

Drug

Study

Sponsor

Population

Region

Study duration

Primary outcome/endpoint

CD 80/86 inhibitor

abatacept

Limit-JIA, NCT03841357

Duke University

OJIA

United States

10/2019–12/2022

Joint count, active anterior uveitis

IL-23 inhibitor

guselkumab

aPROTOSTAR, NCT03451851

Janssen

Paediatric psoriasis

global

7/2018–6/2025

PASI75, PGA ≤1

risankizumab

bM19–977, NCT04435600

Abbvie

Paediatric psoriasis

United States

7/2020–06/2025

PASI75; PGA ≤ 1

tildrakizumab

TILD-19-12, NCT03997786

Sun Pharma Global FZE

Paediatric psoriasis

United States

1/2020–11/2023

PASI75, PGA ≤1

IL-17 inhibitor

brodalumab

cEMBRACE 1, NCT04305327

LEO Pharma

Paediatric psoriasis

global

9/2020–11/2023

PASI75

secukinumab

dCAIN457F2304, NCT03031782

Novartis

PsA, ERA

global

5/2017–12/2020

Disease flare

eCAIN457A2311, NCT03668613

Novartis

Paediatric psoriasis

global

8/2018–9/2023

PASI75, PGA ≤1

fCAIN457A2310, NCT02471144

Novartis

Paediatric psoriasis

global

9/2015–7/2023

PASI75, PGA ≤1

TNF inhibitor

adalimumab

gADJUST, NCT03816397

UCSF

JIA-associated uveitis

United States

12/2019–12/2022

Treatment failure

etanercept

STARS, EudraCT 2018–001931-27

IRCCS Istituto Giannina Gaslini

OJIA, PJIA

Italy

NA

Clinical inactive disease

infliximab

KIDCARE, NCT03065244

UCSD

Kawasaki disease

United States

2/2017–9/2020

Fever

certolizumab pegol

CIMcare, NCT04123795

UCB Biopharma

Paediatric psoriasis

North America

1/2020–4/2023

PASI75, PGA ≤1

JAK inhibitor

baricitinib

hJUVE-BRIGHT, NCT04088409

Eli Lilly

JIA-associated uveitis

Europe

10/2019–7/2022

Uveitis disease response

iJUVE-BALM, NCT04088396

Eli Lilly

SJIA

global

2/2020–4/2023

Disease flare

jJUVE-BASIS, NCT03773978

Eli Lilly

PJIA, extended OJIA, ERA, PsA

global

12/2018–8/2021

Disease flare

tofacitinib

A3921165, NCT03000439

Pfizer

SJIA

global

5/2018–8/2023

Disease flare

  1. Abbreviations: IL interleukin, TNF tumour necrosis factor, JAK Janus Kinase, ERA enthesitis-related juvenile idiopathic arthritis, JIA juvenile idiopathic arthritis, PsA, psoriatic juvenile idiopathic arthritis, OJIA oligoarticular juvenile idiopathic arthritis, PASI psoriasis area and severity index, PGA Physician global assessment, PJIA polyarticular juvenile idiopathic arthritis, SJIA systemic juvenile idiopathic arthritis, NA not applicable
  2. aAlso registered under EudraCT 2017–003053-42; bAlso registered under EudraCT 2019–004141-32, cAlso registered under EudraCT 2019–001868-30; dAlso registered under EudraCT 2016–003761-26; eAlso registered under EudraCT 2017–004515-39; fAlso registered under EudraCT 2014–005663-32; gAlso registered under EudraCT 2019–000412-29; hAlso registered under EudraCT 2019–00119-10; iAlso registered under EudraCT 2017–004495-60; jAlso registered under EudraCT 2017–004518-24